Story
Northrop Grumman Stock Nears 52-Week Low After Losing Key Navy Fighter Contract to Boeing

Summary
Northrop Grumman's stock fell sharply after the Pentagon awarded the multibillion-dollar F/A-XX fighter contract to rival Boeing, raising questions about the defense giant's long-term growth in the manned fighter aircraft segment.
Northrop Grumman (NOC) shares tumbled to near a 52-week low on Wednesday after the Pentagon awarded a major next-generation fighter jet contract to rival Boeing (BA). The decision effectively removes Northrop from the U.S. manned sixth-generation fighter landscape, a significant strategic blow for the defense contractor.
Boeing Secures F/A-XX Program
The Pentagon announced on September 29 that it had selected Boeing for the U.S. Navy’s F/A-XX program, a contract for a next-generation carrier-based stealth fighter. The initial award is valued at over $20 billion and has the potential to expand into hundreds of billions over the program's full lifecycle, according to a report from Investing.com.
This loss is compounded by Boeing's win of the Air Force's sixth-generation F-47 contract in 2025. For Northrop Grumman, being the losing finalist for the F/A-XX marks its exclusion from all currently planned U.S. next-generation manned fighter programs, which are considered once-in-a-generation opportunities for defense primes.
Market Reaction and Technical Outlook
In response to the news, Northrop Grumman's stock fell 4.23% in trading on September 30, extending its six-month decline to approximately 28%. The share price hovered just above its 52-week low of $479.02, a critical technical support level for investors.
AdWhile technical indicators like the Relative Strength Index (RSI) show the stock is in deeply oversold territory, other metrics suggest the downtrend is well-established. Analysts noted that the situation presents a classic "falling knife" dilemma, where a low price does not guarantee an immediate rebound without a new catalyst.
Strategic Implications for Northrop
The contract loss forces a strategic repositioning for Northrop's long-term growth narrative. CEO Kathy Warden had previously identified the F/A-XX as a "top priority" with significant earnings upside, according to Investing.com. While that potential is now off the table, the company's foundational business remains supported by several key franchises, including:
- The B-21 Raider stealth bomber program.
- The Sentinel Intercontinental Ballistic Missile (ICBM) modernization.
- Its growing space and satellite businesses.
The company also maintains strong financial health indicators, including a perfect Piotroski Score of 9 and a history of 22 consecutive years of dividend increases, suggesting a resilient underlying business despite the strategic setback in the fighter jet segment.
Read next
More on Stocks
Defense Sector ETFs Enter Oversold Territory Amid Heavy Selling
Major exchange-traded funds tracking the U.S. aerospace and defense industry have seen a sharp downturn, pushing a key technical indicator into oversold territory and signaling intense recent selling pressure.

European Bank Rally Bifurcates, Shifting Focus to Value Plays Like BNP Paribas
As the broad rally in European banks matures, investors are shifting focus from momentum stocks to undervalued lenders. Data shows French bank BNP Paribas trading at a significant discount despite strong fundamentals, signaling a new phase of stock selection in the sector.

Anthropic's IPO Filing Reveals $2 Trillion Ambition and 'Existential Risk' Warnings
AI firm Anthropic is planning a record-breaking IPO at a $2 trillion valuation, but its draft prospectus warns that its own technology could pose "catastrophic or existential risks to humanity," according to a report.

Alphabet Shares Pare Gains on Report of Internal Doubts Over Gemini 4 AI
Alphabet stock lost momentum Wednesday after a report detailed internal employee skepticism about the real-world performance of its upcoming Gemini 4 AI model. Google has disputed the characterization, calling claims of underperformance inaccurate.